Literature DB >> 27533512

Conjunctival Lymphoma in a Patient on Fingolimod for Relapsing-Remitting Multiple Sclerosis.

Karen L Christopher1, Victor M Elner, Hakan Demirci.   

Abstract

The authors describe a 39-year-old woman treated with fingolimod for relapsing-remitting multiple sclerosis for 2 years who then developed a bilateral conjunctival mucosa-associated lymphoid tissue lymphoma. Fingolimod treatment for multiple sclerosis has been associated with lymphoma in 3 previously reported cases. This is the first case of ocular adnexal lymphoma presumed to be due to fingolimod. Given that ophthalmologists regularly monitor many patients on fingolimod for fingolimod-associated macular edema and ophthalmic manifestations of multiple sclerosis, the authors hope to alert physicians of the possibility of ocular adnexal lymphoma in these patients.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 27533512     DOI: 10.1097/IOP.0000000000000774

Source DB:  PubMed          Journal:  Ophthalmic Plast Reconstr Surg        ISSN: 0740-9303            Impact factor:   1.746


  3 in total

1.  Primary central nervous system lymphoma in a patient with multiple sclerosis using fingolimod.

Authors:  Matheus Bernardon Morillos; Paulo Henrique Pires de Aguiar; Paulo Roberto Franceschini; Juliana Ávila Duarte; Cristian Daniel Piccini; Alessandro Finkelsztejn
Journal:  Neurol Sci       Date:  2022-08-29       Impact factor: 3.830

2.  Intracerebral lymphoproliferative disorder in an MS patient treated with fingolimod.

Authors:  Brigit A de Jong; Zoé L E van Kempen; Mike P Wattjes; Patrick M Smit; Laura Peferoen; Daniella Berry; Martine E D Chamuleau; Daphne de Jong
Journal:  Neurol Neuroimmunol Neuroinflamm       Date:  2018-07-10

Review 3.  Ocular adverse events from pharmacological treatment in patients with multiple sclerosis-A systematic review of the literature.

Authors:  Juliana Muñoz-Ortiz; Juliana Reyes-Guanes; Estefanía Zapata-Bravo; Laura Mora-Muñoz; Juan Antonio Reyes-Hurtado; Luis Octavio Tierradentro-García; William Rojas-Carabali; Marcela Gómez-Suarez; Alejandra de-la-Torre
Journal:  Syst Rev       Date:  2021-10-28
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.